Drug Trial Radar · NCT07220629
Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Oct 2, 2025
Primary completion
Aug 21, 2026
Study completion Aug 21, 2026
Sponsor
- Lead sponsor
- NodThera Ltd. (a Rezera company)Industry
- Sponsor type
- Industry
- First posted
- Oct 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore the safety and efficacy of NT-0796 as an adjunct to semaglutide in participants with obesity over a 6 months treatment period.
Conditions
- Obesity
Interventions
NT-0796Drug
Orally administered capsules
PlaceboDrug
Orally administered capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the safety and tolerability of NT-0796 as an adjunct to semaglutide in participants with obesity by assessing AEs and SAEs, symptoms of nausea and vomiting, clinical laboratory parameters, vital signs and ECGs.Time frame: Baseline to Week 24
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Investigative Site
Mesa, Arizona
Investigative Site
Hialeah, Florida
Investigative Site
Jacksonville, Florida
Investigative Site
Miami, Florida
Investigative Site
Marrero, Louisiana
Investigative Site
Columbus, Ohio
Investigative Site
Seabrook, Texas
Investigative Site
Salt Lake City, Utah
Investigative Site
Manassas, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.